Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck
| Autor: | Masha Kocherginsky, Anna B. Halpern, Everett E. Vokes, Kristen Kasza, R. Williams, Ezra E.W. Cohen |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Pathology Antineoplastic Agents Lapatinib Disease-Free Survival Article Erlotinib Hydrochloride Gefitinib Internal medicine medicine Humans Epidermal growth factor receptor Protein Kinase Inhibitors Aged Retrospective Studies Performance status biology business.industry Age Factors Middle Aged Protein-Tyrosine Kinases medicine.disease Head and neck squamous-cell carcinoma Rash ErbB Receptors Treatment Outcome Head and Neck Neoplasms Carcinoma Squamous Cell Quinazolines biology.protein Female Erlotinib Neoplasm Recurrence Local Oral Surgery medicine.symptom business Progressive disease medicine.drug |
| Zdroj: | Oral Oncology. 45:e155-e160 |
| ISSN: | 1368-8375 |
| DOI: | 10.1016/j.oraloncology.2009.05.637 |
| Popis: | Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have demonstrated reproducible response rates of 5-15% in treatment of squamous cell carcinomas of the head and neck (SCCHN). The subset of patients that benefits most from these agents remains unknown. We reviewed individual patient data from five clinical trials of erlotinib, lapatinib, or gefitinib to determine if there are clinical characteristics that are associated with clinical benefit defined as complete response (CR), partial response (PR), and stable disease (SD) >4months. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Three-hundred and nineteen subjects were included. Observed responses were: 1% CR, 6% PR, 24% SD >4months, 18% SD |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect